Table 6 Subgroup analysis of response rate of SJZT or MSJZT in patients with FD
| Subgroups | No. of trials | No. of patients |
Pooled RR (95% CI); P-value | Pheterogeneity; I2 | |
|---|---|---|---|---|---|
| All studies | 12 | 1383 | 1.23 (1.17, 1.30); P < 0.00001 | 0.03; 47% | |
| Intervention in trial group | SJZT | 1 | 90 | 1.21 (0.99, 1.49); P = 0.06 | Not applicable |
| MSJZT | 8 | 988 | 1.24 (1.16, 1.34); P < 0.00001 | 0.20; 29% | |
| SJZT + conventional medicines | 2 | 245 | 1.17 (0.81, 1.68); P = 0.40 | 0.009; 85% | |
| MSZT + conventional medicines | 1 | 60 | 1.22 (0.98, 1.52); P = 0.08 | Not applicable | |
| Intervention in control group | Placebo | 2 | 118 | 1.74 (1.30, 2.34); P = 0.0002 | 0.34; 0% |
| Conventional medicines | 10 | 1265 | 1.20 (1.15, 1.26); P < 0.00001 | 0.21; 25% |
